{"id":449,"date":"2019-05-17T08:54:48","date_gmt":"2019-05-17T08:54:48","guid":{"rendered":"https:\/\/www.diabetesasia.org\/magazine\/?p=449"},"modified":"2025-04-11T13:46:29","modified_gmt":"2025-04-11T08:16:29","slug":"what-are-the-futuristic-treatment-of-diabetes","status":"publish","type":"post","link":"https:\/\/www.diabetesasia.org\/magazine\/what-are-the-futuristic-treatment-of-diabetes\/","title":{"rendered":"what are the futuristic treatment of diabetes?"},"content":{"rendered":"

Diabetes is a significant reason for visual impairment<\/span><\/strong><\/a>, kidney disappointment<\/span><\/strong><\/a>, heart assault, and stroke. The quantity of individuals influenced by a wide range of diabetic issues is presently more than multiple times higher than only 40 years prior. This has driven the World Health Organization (WHO) to think about diabetes as a plague, foreseeing it will before long be the seventh greatest reason for death around the world.<\/p>\n

Notwithstanding its immense effect, there is still no remedy for diabetes. Most medications help patients deal with the side effects to a limited degree, however, diabetics still face numerous long-haul wellbeing inconveniences.<\/p>\n

The biotech business has seen this chance and is endeavoring to grow new diabetes medications and pursuing the blessed vessel: a fix. How about we view what’s fermenting in the field and how it will change the manner in which diabetes is dealt with?<\/p>\n

CELL THERAPY<\/strong><\/h2>\n

 <\/p>\n

Although still in the very early stages of development, cell therapy<\/a> <\/strong><\/span>is one of the biggest hopes for developing a cure for diabetes, especially for type 1 diabetes<\/span><\/strong><\/a>. Replacing the missing insulin<\/a><\/strong>-producing cells has the potential to recover normal insulin<\/span><\/strong><\/a> production and cure patients.<\/p>\n

\"CELL<\/p>\n

IMMUNOTHERAPY<\/h2>\n

In Type 1 diabetes<\/span><\/strong><\/a>, insulin-delivering cells are dynamically devastated until none are left and the patient completely relies upon insulin injections. Immunotherapy is intended to stop type 1 diabetes. Patients who have been analyzed within the most recent half-year, who still hold some insulin-delivering cells, are given a treatment intended to cause the safe framework to decimate the particular safe cells that are assaulting insulin-creating cells.<\/p>\n

TO DEVELOP A VACCINE OF TYPE 1 DIABETES<\/h2>\n

to delay the progression of type 1 diabetes after an early diagnosis A vaccine has been provided to the patient so that it may be completely cured.<\/p>\n

THE ARTIFICIAL PANCREAS<\/h2>\n

An artificial pancreas<\/span><\/strong><\/a> is a man-made gadget that is intended to discharge insulin because of changing blood glucose levels along these lines to a human pancreas. Counterfeit pancreas frameworks are being contemplated as a conceivable treatment choice for individuals with type 1 diabetes.<\/p>\n

TO INDUCED INSULIN PRODUCTION<\/h2>\n

One of the greatest hits in Type 2 diabetes treatment is glucagon-like peptide (GLP)- 1 receptor agonists, which prompt insulin<\/span><\/strong><\/a> creation in beta-pancreatic cells while stifling the discharge of glucagon. All huge pharma have GLP-1 sedates available or their pipelines, including Sanofi, Eli Lilly, Roche, AstraZeneca, and Boehringer Ingelheim. Be that as it may, Novo Nordisk is going above and beyond with the primary oral variant of a GLP-1 sedate, which is presently near the market.<\/p>\n

\"TO<\/p>\n

MICROBIOME<\/h2>\n

 <\/p>\n

An unequal microbiome organization, known as dysbiosis, has been found in patients with diabetes, for whom the assorted variety of the gut microbiome is regularly diminished when contrasted with sound individuals. Specialists from the University of Amsterdam as of late demonstrated that fecal transplants, used to exchange the microbiome of a solid individual to the gut of one with diabetes, can result in a transient improvement of the insulin<\/span><\/strong><\/a> opposition found in stout patients with type 2 diabetes<\/span><\/strong><\/a>.<\/p>\n

The needle-free revolution<\/b><\/h2>\n

In a perfect world, blood sugar testing would be quick and painless,\u201d <\/i>said Avner Gal, CEO of Integrity Applications in an interview. That world may not be so far away, as many companies are developing non-invasive methods to substitute finger pricking.<\/p>\n

Gal\u2019s company, Integrity Applications, has developed a device called GlucoTrack that can measure glucose using electromagnetic waves and is already available in Europe.<\/p>\n

Similar technologies are popping up, with GlucoSense in London using laser light to measure sugar levels and MediWise making use of radio waves. \u201dThe device could reduce costs for healthcare, which in the case of diabetes account.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"

Diabetes is a significant reason for visual impairment, kidney disappointment, heart assault, and stroke. The…<\/p>\n","protected":false},"author":2,"featured_media":8978,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[25,17,19,1],"tags":[123,122,189,125,124,190],"class_list":["post-449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diabetes-research-update","category-type-1-diabetes","category-type-2-diabetes","category-uncategorized","tag-cell-therapy","tag-diabetes-in-future","tag-diabetes-insipidus","tag-immunotherapy","tag-insuline-therapy","tag-treatment-of-insipidus"],"aioseo_notices":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.diabetesasia.org\/magazine\/wp-content\/uploads\/2019\/05\/A1main-041819.jpg?fit=1000%2C563&ssl=1","jetpack_sharing_enabled":true,"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/posts\/449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/comments?post=449"}],"version-history":[{"count":3,"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/posts\/449\/revisions"}],"predecessor-version":[{"id":8979,"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/posts\/449\/revisions\/8979"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/media\/8978"}],"wp:attachment":[{"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/media?parent=449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/categories?post=449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.diabetesasia.org\/magazine\/wp-json\/wp\/v2\/tags?post=449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}